Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: Results from the Dallas Heart Study - 07/08/11
, Darren K. McGuire, MD, MHSc a, Amit Khera, MD, MSc a, Sandeep R. Das, MD, MPH a, Sabina A. Murphy, MPH b, Torbjorn Omland, MD, PhD, MPH c, Mark H. Drazner, MD, MSc aRésumé |
Background |
Identification of individuals in the community with left ventricular systolic dysfunction (LVSD) or left ventricular hypertrophy (LVH) may allow earlier initiation of disease-modifying treatment. We performed a comprehensive evaluation of the screening performance of B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) for LVSD or LVH.
Methods |
In 2,429 subjects without a history of heart failure, myocardial infarction, valvular abnormalities, or a serum creatinine >2.0 mg/dL enrolled in the Dallas Heart Study, measurement of BNP and NT-proBNP and cardiovascular magnetic resonance imaging were performed.
Results |
B-type natriuretic peptide and NT-proBNP were robustly associated with magnetic resonance imaging–defined LVH and LVSD (ejection fraction <55%) among men and women (P < .0001 for each). In the overall population, neither test discriminated well for LVH or LVSD (area under the receiver operating characteristic curve [AUROC] <0.7). Among women, no differences in AUROC were observed between BNP and NT-proBNP. Among men, AUROCs were similar between BNP and NT-proBNP in the overall population, but among subgroups age 50 or older, or with hypertension, the AUROCs for NT-proBNP (0.73-0.79) were higher than for BNP (0.63-0.69, P < .05 for each comparison). Compared with subjects with isolated BNP elevation (>97.5th percentile), those with isolated NT-proBNP elevation had worse renal function and more LVH and coronary calcium (P < .05 for each).
Conclusions |
Overall, neither BNP nor NT-proBNP accurately discriminated subjects with LVH or LVSD in this predominately young and healthy population-based cohort. However, among high-risk men, NT-proBNP performed slightly better than BNP and comparably with other routinely used screening tests such as prostate-specific antigen measurement for prostate cancer.
Le texte complet de cet article est disponible en PDF.Plan
Vol 157 - N° 4
P. 746 - avril 2009 Retour au numéro
Article précédent
- Impact of female gender and transradial coronary stenting with maximal antiplatelet therapy on bleeding and ischemic outcomes
- Helena Tizón-Marcos, Olivier F. Bertrand, Josep Rodés-Cabau, Éric Larose, Valérie Gaudreault, Rodrigo Bagur, Onil Gleeton, Javier Courtis, Louis Roy, Paul Poirier, Olivier Costerousse, Robert De Larochellière
- Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF
- Clyde W. Yancy, Gregg C. Fonarow, Nancy M. Albert, Anne B. Curtis, Wendy Gattis Stough, Mihai Gheorghiade, J. Thomas Heywood, Mark L. McBride, Mandeep R. Mehra, Christopher M. O'Connor, Dwight Reynolds, Mary Norine Walsh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?